Testosterone as a predictor of pathological stage in clinically localized prostate cancer

Journal of Urology

Volumn 173, Issue 6, 2005, Pages 1935-1937

  Isom Batz, Ginger ^a   Blanco Jr , Fernando J ^a   Kattan, Michael W ^a   Mulhall, John P ^a   Lilja, Hans ^a   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Disease progression; Prostate; Prostatectomy; Prostatic neoplasms; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

CANCER ADJUVANT THERAPY; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATHOLOGY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TESTOSTERONE BLOOD LEVEL;

EID: 18744369944     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000158040.33531.e7     Document Type: Article

References (20)

1. Prehn, R. T.: On the prevention and therapy of prostate cancer by androgen administration. Cancer Res, 59: 4161, 1999
2. Lucia, M. S., Bostwick, D. G., Bosland, M., Cockett, A. T., Knapp, D. W., Leav, I. et al: Workgroup I: rodent models of prostate cancer. Prostate, 36: 49, 1998
3. Bladou, F., Vessella, R. L., Buhler, K. R., Ellis, W. J., True, L. D. and Lange, P. H.: Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer, 67: 785, 1996
4. Stattin, P., Lumme, S., Tenkanen, L., Alfthan, H., Jellum, E., Hallmans, G. et al: High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer, 108: 418, 2004
5. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C. and Stampfer, M. J.: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst, 88: 1118, 1996
6. Dorgan, J. F., Albanes, D., Virtamo, J., Heinonen, O. P., Chandler, D. W., Galmarini, M. et al: Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev, 7: 1069, 1998
7. Chodak, G. W., Vogelzang, N. J., Caplan, R. J., Soloway, M. and Smith, J. A.: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA, 265: 618, 1991
8. Ribeiro, M., Ruff, P. and Falkson, G.: Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol, 20: 605, 1997
9. Ohori, M., Kattan, M. W., Koh, H., Maru, N., Slawin, K. M., Shariat, S. et al: Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol, 171: 1844, 2004
10. Soloway, M. S., Pareek, K., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr. et al: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol, 167: 112, 2002
11. Massengill, J. C., Sun, L., Moul, J. W., Wu, H., McLeod, D. G., Amling, C. et al: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol, 169: 1670, 2003
12. Imamoto, T., Suzuki, H., Akakura, K., Komiya, A., Nakamachi, H., Ichikawa, T. et al: Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J, 48: 573, 2001
13. Hoffman, M. A., DeWolf, W. C. and Morgentaler, A.: Is low serum free testosterone a marker for high grade prostate cancer? J Urol, 163: 824, 2000
14. Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G. et al: The influence of finasteride on the development of prostate cancer. N Engl J Med, 349: 215, 2003
15. Scardino, P. T.: The prevention of prostate cancer-the dilemma continues. N Engl J Med, 349: 297, 2003
16. Morgentaler, A., Bruning, C. O., 3rd and DeWolf, W. C.: Occult prostate cancer in men with low serum testosterone levels. JAMA, 276: 1904, 1996
17. Schatzl, G., Madersbacher, S., Haitel, A., Gsur, A., Preyer, M., Haidinger, G. et al: Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol, 169: 1312, 2003
18. Zagars, G. K., Pollack, A. and von Eschenbach, A. C.: Serum testosterone-a determinant of metastatic relapse for irradiated localized prostate cancer. Urology, 49: 327, 1997
19. Iversen, P., Rasmussen, F. and Christensen, I. J.: Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl, 157: 41, 1994
20. Miller, L. R., Partin, A. W., Chan, D. W., Bruzek, D. J., Dobs, A. S., Epstein, J. I. et al: Influence of radical prostatectomy on serum hormone levels. J Urol, 160: 449, 1998